
Following a successful financial year 2020, German family-owned pharma major Boehringer Ingelheim says it has continued its positive trend in the first half of 2021.
In the first six months, the company generated net sales of 9.8 billion euros ($11.6 billion), up 5.8% (year on year and adjusted for currency effects). All three business areas (Human Pharma, Animal Health, Biopharmaceutical Contract Manufacturing) contributed to the net sales growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze